



Possible Acquisition of Beijing Puxiang Investment Management Co. Ltd. By Besunyen at a Consideration of RMB488 million

(16 December 2014, Hong Kong) - **Besunyen Holdings Company Limited**, a leading provider of therapeutic teas in China, (**“Besunyen”** or the **“Company”**; **stock code: 926**; **together with its subsidiaries, the “Group”**) has announced that the Company has entered into a non-legally binding term sheet in relation to the possible acquisition of the entire equity interest in **Beijing Puxiang Investment Management Co. Ltd. (“Beijing Puxiang”)**. Upon the completion of the possible acquisition, Beijing Puxiang and its subsidiaries (the **“Target Group”**) will become subsidiaries of the Company.

Pursuant to the term sheet, the Company proposed to acquire the entire equity interest in Beijing Puxiang in order to control several significant subsidiaries of Beijing Puxiang engaging in the operation of medical business. The consideration, being approximately RMB488 million will be satisfied by the issue and the allotment of approximately 610 million consideration shares, representing approximately 38.89% of the existing issued share capital of the Company as at 15 December 2014 and approximately 28% of the total issued share capital of the Company as enlarged by issue of the consideration shares. The Target Group is principally engaged in the operation of medical business in China.

Upon the completion of the possible acquisition, the Company or its subsidiary proposed to inject capital of approximately RMB300 million for the future possible acquisition of medical institutions in China or other projects which the board considers appropriate.

Mr. ZHAO Yihong, Chairman, Executive Director and CEO of Besunyen, said, “In order to expand the principal business of the Company and reach the strategic objective of the Company for developing the Big Health field, we plan to acquire Beijing Puxiang so as to enter into the medical industry, with the expectation to bring more profits to our shareholders.”

-END-

About Besunyen Holdings Company Limited

The Group is a leading provider of therapeutic teas in China, mainly engaging in the operations on the R&D, production, sales, advertising and promotion of therapeutic teas. The products of the Group are formulated by using high quality Chinese herbs along with tea leaves, which provide people who suffer chronic health problems or seek to maintain health with effective, safe, affordable and convenient solutions. Two best-selling products, named Besunyen Detox Tea and Besunyen Slimming Tea, contribute the most of sales revenue to the Group. In 2013, both of Besunyen Detox Tea and Besunyen Slimming Tea continuously outperformed in the leadership positions with their market shares of 22.7% and 38.2% respectively.

This press release is distributed by Wonderful Sky Financial Group Limited on behalf of Besunyen Holdings Company Limited.

For further information, please contact:

Wonderful Sky Financial Group Limited

Public Relations

Abbey Zhao / Sabrina Lu / Chloe Chiu

Tel : (852) 3970 2150 / 3970 2118 / (852) 3970 2279

Fax : (852) 2815 1352

E-mail: abbeyzhao@wsfg.hk / sabrinalu@wsfg.hk / chloechiu@wsfg.hk

Media Relations

Connie Liu

Tel: (852) 3970 2290

Fax: (852) 2815 1352

Email: connieliu@wsfg.hk